Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3712
Source ID: NCT00361868
Associated Drug: Fenofibrate (F) + Metformin (M) Hydrochloride Fixed Combination
Title: Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Dyslipidemia|Glucose Metabolism Disorder
Interventions: DRUG: fenofibrate (F) + metformin (M) hydrochloride fixed combination|DRUG: Rosiglitazone
Outcome Measures: Primary: HbA1c/TG, 24 weeks | Secondary: Lipid and glycemic parameters., 24 weeks
Sponsor/Collaborators: Sponsor: Solvay Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 88
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2006-06
Completion Date: 2007-12
Results First Posted:
Last Update Posted: 2008-06-27
Locations: Site105, Pula, Croatia|Site102, Rijeka, Croatia|Site103, Split, Croatia|Site104, Varazdin, Croatia|Site100, Zagreb, Croatia|Site101, Zagreb, Croatia|Site 205, Jyväskylä, Finland|Site 206, Kokkola, Finland|Site 208, Laukaa, Finland|Site 207, Oulu, Finland|Site 303, Bassens, France|Site 307, Bordeaux, France|Site 305, Murs Erigne, France|Site 302, Seysses, France|Site 304, Strasbourg, France|Site 301, Thouars, France|Site 306, Vihiers, France|Site 405, Berlin, Germany|Site 410, Borna, Germany|Site 403, Bretten, Germany|Site 402, Dresden, Germany|Site 404, Frankfurt, Germany|Site 400, Freiburg, Germany|Site 401, Hannover, Germany|Site 409, Ilvesheim, Germany|Site 411, Ilvesheim, Germany|Site 407, Leipzig, Germany|Site 406, Rodgau, Germany|Site 413, Rotenburg, Germany|Site 408, Schwerin, Germany|Site 412, Villingen-Schwenningen, Germany|Site 509, Almere, Netherlands|Site 502, Breda, Netherlands|Site 503, Eindhoven, Netherlands|Site 504, Groningen, Netherlands|Site 505, Leiden, Netherlands|Site 506, Nijmegen, Netherlands|Site 500, Rotterdam, Netherlands|Site 507, Velp, Netherlands|Site 508, Zoetermeer, Netherlands|Site 610, Bialystok, Poland|Site 606, Elblag, Poland|Site 608, Gdansk, Poland|Site 600, Lodz, Poland|Site 605, Otolinska, Poland|Site 604, Radom, Poland|Site 613, Starogard Gdanski, Poland|Site 601, Warszawa, Poland|Site 607, Warszawa, Poland|Site 612, Warszawa, Poland|Site 602, Wroclaw, Poland|Site 603, Wroclaw, Poland|Site 704, Brasov, Romania|Site 701, Bucharest, Romania|Site 703, Bucharest, Romania|Site 700, Cluj-Napoca, Romania|Site 702, Iasi, Romania|Site 705, Targu-Mures, Romania|Site 807, Kharkiv, Ukraine|Site 811, Kharkiv, Ukraine|Site 812, Kharkiv, Ukraine|Site 800, Kiev, Ukraine|Site 803, Kiev, Ukraine|Site 808, Kiev, Ukraine|Site 809, Kiev, Ukraine|Site 810, Kiev, Ukraine|Site 813, Kiev, Ukraine|Site 805, Lviv, Ukraine|Site 804, Odessa, Ukraine|Site 802, Vinnitsa, Ukraine
URL: https://clinicaltrials.gov/show/NCT00361868

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D311 Fenofibrate small molecule DB01039 Details
D089 Metformin small molecule DB00331 Details
D116 Rosiglitazone small molecule DB00412 Details